RxDoctor Payments Data

Sarah Mainzinger

Acute Care · Toledo, OHNPI 1154942100

Payments from drug & device makers

$2,449in general payments, 2019–2025

Across 99 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$790
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$327
  • AstraZeneca$228
  • Novartis$198
  • Boehringer Ingelheim$159
  • Pfizer$125
  • plus $621 from 15 others

What the payments were for

  • Food & beverage$2,34996%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,449 in reported general payments places this provider in the 90th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$14,906
Medicare patients
141
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$342,006
XareltoRivaroxaban146$122,918
EntrestoSacubitril/Valsartan36$39,923
JardianceEmpagliflozin20$22,751
FarxigaDapagliflozin Propanediol13$12,696
Repatha SureclickEvolocumab15$9,984
Dofetilide44$7,834
Flecainide Acetate156$6,800
Amiodarone Hcl160$6,378
Metoprolol Succinate276$4,744
Diltiazem 24hr Er (Cd)Diltiazem Hcl103$2,757
SotalolSotalol Hcl119$2,475
Mexiletine Hcl17$2,312
Atorvastatin Calcium169$1,723
Diltiazem 24hr Er (La)Diltiazem Hcl12$1,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$342,006324 claims
Johnson & JohnsonXarelto$29$122,918146 claims
NovartisEntresto$198$39,92336 claims
Boehringer IngelheimJardiance$159$22,75120 claims
AstraZenecaFarxiga$228$12,69613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,101 acute care providers in Ohio.

Other acute care in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →